𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

✍ Scribed by J. C. MANSFIELD; M. PARKES; A. B. HAWTHORNE; A. FORBES; C. S. J. PROBERT; R.C. PEROWNE; A. COOPER; J. B. ZELDIS; D. C. MANNING; C. J. HAWKEY

Book ID
108605016
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
563 KB
Volume
26
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont
A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease
✍ J. P. Wright; Dr. D. P. Jewell; R. Modigliani; H. Malchow 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB 👁 2 views

Olsalazine, consisting of two salicylate radicals linked by an azo-bond, is effective in the treatment of active ulcerative colitis. To test its effect in patients with mild to moderate attacks of Crohn's disease, the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) des

Randomized, double-blind, placebo-contro
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients

Fontolizumab in moderate to severe Crohn
Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
✍ Walter Reinisch; Williem de Villiers; László Bene; László Simon; István Rácz; Se 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 285 KB

## Background: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptom

Randomized, placebo-controlled, double-b
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
✍ Andrea Martinuzzi; Alexandra Liava; Enrico Trevisi; Mara Frare; Caterina Tonon; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin‐converting enzyme (ACE) insertion (I)/deletion (D) haplotype—patients with the genotype associated with higher ACE activity show the most severe